Dame Emma Natasha Walmsley DBE is the chief executive officer (CEO) of GlaxoSmithKline plc (GSK). Emma was appointed to the Board as Chief Executive Officer Designate on 1 January 2017 and became Chief Executive Officer on 1 April 2017. She is a member of the Corporate Executive Team.
Since taking the helm of the 300-year-old company, Emma led a global restructuring program aimed at saving more than $500 million a year by 2021. In one of her biggest moves since becoming CEO, She led the $13 billion dollar purchase of Novartis’s 36% stake in GSK Consumer Health.
Title: Chief Executive Officer
Company: Glaxosmithkline PLC
Country: United Kingdom
Prior to becoming Chief Executive Officer, Emma was the CEO of GSK Consumer Healthcare, a Joint Venture between GSK and Novartis, from its creation in March 2015, and has been a member of GSK’s Corporate Executive Team since 2011. She joined GSK in 2010, with responsibility for Consumer Healthcare, Europe.
Before joining GSK in 2010, Emma worked with L’Oreal for 17 years where she held a variety of marketing and general management roles in Paris, London and New York. From 2007 she was based in Shanghai as General Manager, Consumer Products for L’Oreal China.
Emma joined the Microsoft board as an independent director in December 2019. She was a Non-Executive Director of Diageo plc from January to September 2016.
Emma was appointed Dame (DBE) for services to the pharmaceutical industry and business in the 2020 British Honours. She holds an MA in Classics and Modern Languages from Oxford University.